I know that this is different from what I'd posted last night... but I don't think the company will PR TLD beforehand, due to their obligations to the journal that they are working with.
If the journal were to publish prior to the event, then they could, but I don't have any insights as to how that process is moving forward, only that it seems to be moving forward.
From what I understand, an outsider to the company, such as LL, who is the Principal Investigator for the trial, can talk to the P3 data in a scientific conference.
It seems that them's the rules.